Boston Scientific Corp (BSX) 24.17 $BSX Boston

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Boston Scientific Corp (BSX) 24.17 $BSX

Boston Scientific To Participate In Canaccord Genuity Growth Conference And Wedbush PacGrow Healthcare Conference
PR Newswire - Mon Aug 01, 7:30AM CDT
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare Conference on August 16 in New York.
BSX: 24.17 (-0.26)

Ford and Whole Foods skid, Alere and Facebook jump
AP - Thu Jul 28, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:
BSX: 24.17 (-0.26), WFM: 30.16 (-0.25), F: 11.94 (-0.54), FB: 123.09 (-1.22), ALR: 36.59 (-0.38), GRPN: 5.10 (+0.11), MOH: 57.02 (+0.86)

Boston Scientific (BSX) Meets Q2 Earnings Estimate, Views Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:03PM CDT
Boston Scientific Corporation (BSX) announced adjusted EPS of 27 cents in the second quarter of 2016, up 22.7% from the year-ago quarter.
BSX: 24.17 (-0.26), GWPH: 94.07 (-2.04), BAX: 48.48 (-0.02), VASC: 45.35 (-1.10)

Boston Scientific posts strong sales and boosts its outlook
AP - Thu Jul 28, 12:37PM CDT
NEW YORK (AP) — Boston Scientific's stock traded higher Thursday after the medical device maker reported better-than-expected second-quarter sales and raised its forecasts for the year.
BSX: 24.17 (-0.26)

Boston Scientific (BSX) Breaks Through Resistance at $24.01
Comtex SmarTrend(R) - Thu Jul 28, 9:20AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $23.76 and have already reached the first level of resistance at $24.01. Analysts will be watching for a cross of the next upside pivot targets of $24.35 and $24.94.
BSX: 24.17 (-0.26)

Boston Scientific (BSX) Posts In-Line Q2 Earnings, View Up
Aparajita Dutta - Zacks Investment Research - Thu Jul 28, 7:19AM CDT
Boston Scientific's (BSX) adjusted earnings of 27 cents per share came in line with the Zacks Consensus estimate.
BSX: 24.17 (-0.26)

Boston Scientific Announces Results For Second Quarter 2016
PR Newswire - Thu Jul 28, 5:30AM CDT
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to $2.060 billion. This represents growth of 15 percent on a reported basis and 16 percent on an operational basis (calculated on a constant currency basis), all compared to the prior year period. The company reported a GAAP loss of $207 million, or $(0.15) per share, compared to earnings of $0.08 a year ago, and achieved adjusted earnings per share of $0.27 for the period, compared to $0.22 a year ago.
BSX: 24.17 (-0.26)

Shares of BSX Up 31.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 28, 12:44AM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 5 months, Boston Scientific has returned 31.41% as of today's recent price of $23.66.
BSX: 24.17 (-0.26)

After Yesterday's Decline of 1.61%, Boston Scientific Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 27, 2:32PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $23.53 to a high of $24.11. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $23.62 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BSX: 24.17 (-0.26)

NuVasive (NUVA) Beats on Q2 Earnings, Raises FY16 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:27PM CDT
NuVasive, Inc. (NUVA) reported second-quarter 2016 adjusted earnings per share (EPS) of 40 cents, reflecting a 29% rise from the year-ago quarter.
BSX: 24.17 (-0.26), ZBH: 130.59 (-0.47), GWPH: 94.07 (-2.04), NUVA: 62.63 (-0.66)

C.R. Bard (BCR) Beats Q2 Earnings & Sales, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:19PM CDT
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.56 in the second quarter of 2016, exceeding the Zacks Consensus Estimate by a dime.
HYH: 33.84 (-0.23), BSX: 24.17 (-0.26), BCR: 222.63 (-2.52), ALGN: 90.38 (+0.69)

Boston Scientific Announces Acquisition of Cosman Medical
PR Newswire - Wed Jul 27, 8:00AM CDT
Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Cosman Medical, Inc., a privately held Burlington, Mass. manufacturer of radiofrequency ablation (RFA) systems. The Cosman Medical team and products will become part of the Boston Scientific Neuromodulation business, which offers a range of Spinal Cord Stimulator (SCS) systems to treat patients with chronic pain, and Deep Brain Stimulation systems* for the treatment of Parkinson's disease, dystonia and essential tremor.
BSX: 24.17 (-0.26)

Look at Medical Product Earnings on Jul 28: BSX, RMD & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:59AM CDT
Medical is one of the seven broader sectors among the 16 Zacks sectors to report earnings growth this season.
BSX: 24.17 (-0.26), SRDX: 27.69 (+0.63), ZBH: 130.59 (-0.47), VIVO: 19.29 (-0.26), RMD: 69.38 (-0.47)

PetMed (PETS) Tops Q1 Earnings, Lags Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 1:08PM CDT
PetMed Express, Inc. (PET) announced earnings per share (EPS) of 32 cents in the first quarter of fiscal 2017, up 10.3% from the year-ago quarter.
BSX: 24.17 (-0.26), STMP: 77.35 (-0.78), EVLV: 1.89 (-0.03)

Chemed (CHE) Lags Q2 Earnings, Tops Revenues, View Up
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:59AM CDT
Chemed???s (CHE) second-quarter 2016 results were a mixed bag with its bottom-line lagging behind the Zacks Consensus Estimate while revenues exceeded the same
CHE: 145.13 (-1.94), BSX: 24.17 (-0.26), NUVA: 62.63 (-0.66)

Baxter International (BAX) Q2 Earnings, Sales Top; View Up
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:25AM CDT
Baxter International Inc (BAX) reported second-quarter 2016 adjusted earnings of 46 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents.
BSX: 24.17 (-0.26), BAX: 48.48 (-0.02), BXLT: 46.02 (-0.18), NUVA: 62.63 (-0.66)

Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:24PM CDT
Alere Inc. (ALR) lowered revenue estimate for the year that ended on Dec 31, 2015 and also offered some Q1 figures.
BSX: 24.17 (-0.26), ABT: 45.07 (-0.22), ALR: 36.59 (-0.38), NUVA: 62.63 (-0.66)

Will AmSurg's Merger with Envision Healthcare Drive Growth?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:08PM CDT
AmSurg (AMSG) recently agreed to merge in an all-stock deal with Envision Healthcare to create one of the largest providers of physician services in the U.S.
AMSG: 72.04 (-0.19), BSX: 24.17 (-0.26), EVHC: 23.54 (-0.05), GWPH: 94.07 (-2.04), NUVA: 62.63 (-0.66)

Zacks.com featured highlights: J. M. Smucker, Energizer Holdings, Boston Scientific, Tahoe Resources and Owens Corning
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 8:30AM CDT
Zacks.com featured highlights: J. M. Smucker, Energizer Holdings, Boston Scientific, Tahoe Resources and Owens Corning
BSX: 24.17 (-0.26), OC: 53.96 (+0.40), TAHO: 15.66 (-0.04), ENR: 50.94 (-0.99), SJM: 154.58 (+0.30)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 26

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

NuCana Discontinues Phase 2 Colorectal Cancer Study

Updated Category News Views 146

NuCana Provides Update on Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study Discontinued Following Initial Analysis Ongoing Studies Show Promise with NUC-7738 and Pembrolizumab NuCana plc (NASDAQ: NCNA) has shared important updates about its clinical trials focused on innovative treatments for colorectal cancer. The company has made the decision to discontinue...

Continue Reading
Brøndbyernes IF Football Meeting - Key Highlights Recap

Updated Category News Views 179

Overview of the Annual General Meeting for Brøndbyernes IF Football A/S BRØNDBYERNES I.F. FODBOLD A/S CVR-nr. 83 93 34 10 This report summarizes the outcomes of the annual general meeting conducted by Brøndbyernes IF Football A/S. Key Date and Location The annual shareholders meeting took place, gathering stakeholders and shareholders at the club's headquarters. A...

Continue Reading
Uncovering the Wealth from Investing in BlackRock

Updated Category News Views 314

The Potential Growth of $1000 in BlackRock Investors often wonder how their money would grow over time if invested in strong companies. Recently, we looked into BlackRock, Inc., known by its stock ticker BLK. Over a span of 15 years, investing just $1000 into BlackRock stocks would yield an impressive value today. According to current evaluations, if you had made that...

Continue Reading
Zealand Pharma Advances Glepaglutide Approval for SBS Treatment

Updated Category News Views 267

Glepaglutide Submission to EMA Marks Significant Progress Zealand Pharma A/S, a pioneering biotechnology company, has recently shared exciting news about its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its innovative drug, glepaglutide. This long-acting GLP-2 analog is specifically designed for treating adults suffering from short...

Continue Reading
Seven Gables Real Estate Partners with Local Logic for Insights

Updated Category News Views 40

Seven Gables Real Estate Partners with Local Logic In a significant move that underscores their dedication to innovation, Seven Gables Real Estate has announced an exciting partnership with Local Logic, a leader in location intelligence. This collaboration is set to incorporate Local Logic's cutting-edge products—Local Content, Local Search, and NeighborhoodWrap—into...

Continue Reading